Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Microbiology and Immunology
Published in: Medical Microbiology and Immunology 4/2007

01-12-2007 | Review

The threat of avian influenza A (H5N1). Part III: antiviral therapy

Authors: Jindrich Cinatl Jr, Martin Michaelis, Hans W. Doerr

Published in: Medical Microbiology and Immunology | Issue 4/2007

Login to get access

Abstract

Among emerging and re-emerging infectious diseases, influenza constitutes one of the major threats to mankind. In this review series epidemiologic, virologic and pathologic concerns raised by infections of humans with avian influenza virus A/H5N1 as well as treatment options are discussed. The third part discusses therapeutic options. Neuraminidase (NA) inhibitors are the most promising agents despite uncertainty about efficacy. Dosage increase, prolonged treatment or combination therapies may increase treatment efficacy and/or inhibit resistance formation. Immune system dysregulation contributes to H5N1 disease. Although current evidence does not support the use of anti-inflammatory drugs beneficial effects cannot be excluded at later disease stages.
Literature
1.
Webster RG, Govorkova EA (2006) H5N1 influenza-continuing evolution and spread. N Engl J Med 355:2174–7PubMedCrossRef
2.
Cinatl J Jr, Michaelis M, Doerr HW (2007) The threat of avian influenza A (H5N1)-part I: epidemiologic concerns and virulence determinants. Med Microbiol Immunol (in press)
3.
Schünemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, Hayden FG, Yazdanpanah Y, Beigel J, Chotpitayasunondh T, Del Mar C, Farrar J, Tran TH, Ozbay B, Sugaya N, Fukuda K, Shindo N, Stockman L, Vist GE, Croisier A, Nagjdaliyev A, Roth C, Thomson G, Zucker H, Oxman AD; WHO rapid advice guideline panel on avian influenza (2007)WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 7:21–31PubMedCrossRef
4.
The writing committee of the World Health Organization (WHO) consultation on human influenza A/H5 (2005) Avian influenza A (H5N1) infection in humans. N Engl J Med 353:1374–1385CrossRef
5.
Cinatl J Jr, Michaelis M, Doerr HW (2007) The threat of avian influenza A (H5N1)-part II: Clues to the pathology. Med Microbiol Immunol (in press)
6.
de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, Hoang DM, Chau NV, Khanh TH, Dong VC, Qui PT, Cam BV, Ha do Q, Guan Y, Peiris JS, Chinh NT, Hien TT, Farrar J (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12:1203–1207PubMedCrossRef
7.
Cheung CL, Rayner JM, Smith GJ, Wang P, Naipospos TS, Zhang J, Yuen KY, Webster RG, Peiris JS, Guan Y, Chen H (2006) Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 193:1626–1629PubMedCrossRef
8.
de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH, Farrar J (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353:2667–2672PubMedCrossRef
9.
Davies WL, Grunert RR, Haff RF, Mcgahen JW, Neumayer EM, Paulshock M, watts JC, Wood TR, Hermann EC, Hoffmann CE (1964) Antiviral activity of 1-adamantanamine (amantadine). Science 144:862–863PubMedCrossRef
10.
Tsunoda A, Maassab HF, Cochran KW, Eveland WC (1965) Antiviral activity of alpha-methyl-1-adamantanemethylamine hydrochloride. Antimicrob Agents Chemother 5:553–560PubMed
11.
Hayden FG (2006) Antiviral for influenza: historical perspectives and lessons learned. Antiviral Res 71:372–378PubMedCrossRef
12.
Hay AJ (1992) The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel proteins. Semin Virol 3:21–30
13.
Chizhmakov IV, Geraghty FM, Ogden DC, Hayhurst A, Antoniou M, Hay AJ (1996) Selective proton permeability and pH regulation of the influenza virus M2 channel expressed in mouse erythroleukaemia cells. J Physiol 494:329–336PubMed
14.
Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH (1985) The molecular basis of the specific anti-influenza action of amantadine. EMBO J 4:3021–3024PubMed
15.
Ruigrok RW, Hirst EM, Hay AJ (1991) The specific inhibition of influenza A virus maturation by amantadine: an electron microscopic examination. J Gen Virol 72:191–194PubMed
16.
17.
Monto AS (2006) Vaccines and antviral drugs in pandemic preparedness. Emerg Infect Dis 12:55–60PubMed
18.
Monto AS, Gunn RA, Bandyk MG, King CL (1979) Prevention of Russian influenza by amantadine. JAMA 241:1003–1007PubMedCrossRef
19.
20.
Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W (1989) Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 321:1696–1702PubMedCrossRef
21.
Abed Y, Goyette N, Boivin G (2005) Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob Agents Chemother 49:556–559PubMedCrossRef
22.
Hayden FG, Hay AJ (1992) Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 176:119–130PubMed
23.
Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y (2003) High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 188:57–61PubMedCrossRef
24.
Boivin G, Goyette N, Bernatchez H (2002) Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin Infect Dis 34:E23–25PubMedCrossRef
25.
Saito R, Sakai T, Sato I, Sano Y, Oshitani H, Sato M, Suzuki H (2003) Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2. J Clin Microbiol 41:2164–2165PubMedCrossRef
26.
Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, Povinelli L, Cox NJ, Klimov AI (2005) Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366:1175–1181PubMedCrossRef
27.
Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI (2006) Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA 295:891–984PubMedCrossRef
28.
Ilyushina NA, Govorkova EA, Russel CJ, Hoffmann E, Webster RG (2007) Contribution of H7 haemagglutinin to amantadine resistance and infectivity of influenza virus. J Gen Virol 88:1266–1274PubMedCrossRef
29.
Li KS, Guan Y, Wang J, Smith GJ, Xu KM, Duan L, Rahardjo AP, Puthavathana P, Buranathai C, Nguyen TD, Estoepangestie AT, Chaisingh A, Auewarakul P, Long HT, Hanh NT, Webby RJ, Poon LL, Chen H, Shortridge KF, Yuen KY, Webster RG, Peiris JS (2004) Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430:209–213PubMedCrossRef
30.
Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG (2007) Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 73:228–231PubMedCrossRef
31.
32.
Palese P, Tobita K, Ueda M, Compans RW (1974) Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61:397–410PubMedCrossRef
33.
Palese P, Compans RW (1976) Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 33:159–163PubMedCrossRef
34.
Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD (2004) Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 78:12665–12667PubMedCrossRef
35.
Ohuchi M, Asaoka N, Sakai T, Ohuchi R (2006) Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect 8:1287–1293PubMedCrossRef
36.
Boivin G, Goyette N (2002) Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Res 54:143–147PubMedCrossRef
37.
Wetherall NT, Trivedi T, Zeller J, Hodges-Savola C, McKimm-Breschkin JL, Zambon M, Hayden FG (2003) Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 41:742–750PubMedCrossRef
38.
Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnenb AM, Hirst HM, Keene O, Wightman K (1997) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 influenza study group. N Engl J Med 337:874–880PubMedCrossRef
39.
Makela MJ, Pauksens K, Rostila T, Fleming DM, Man CY, Keene ON, Webster A (2000) Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 40:42–48PubMedCrossRef
40.
Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rode A, Kinnersley N, Ward P (2000) Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase inhibitor flu treatment investigator group. Lancet 355:1845–1850PubMedCrossRef
41.
Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG (2000) Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US oral neuraminidase study group. JAMA 283:1016–1024PubMedCrossRef
42.
Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, Wat C, Griffiths M, Waalberg E, Ward P; IMPACT Study Group (2003) Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 51:123–129PubMedCrossRef
43.
Hedrick JA, Barzilai A, Behre U, Henderson FW, Hammond J, Reilly L, Keene O (2000) Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 19:410–417PubMedCrossRef
44.
Lalezari J, Campion K, Keene O, Silagy C (2001) Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 161:212–217PubMedCrossRef
45.
Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P (2001) Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20:127–133PubMedCrossRef
46.
Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F (2003) Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 163:1667–1672PubMedCrossRef
47.
Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliot MJ, Hammond JM, Sharp SJ, Ossi MJ; Zanamivir Family Study Group (2000) Inhaled zanamivir for the prevention of influenza in families. Zanamivir family study group. N Engl J Med 343:1282–1289PubMedCrossRef
48.
Hayden FG, Belshe R, Villanueva C, Lanno R, Hughes C, Small I, Dutkowski R, Ward P, Carr J (2004) Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 189:440–449PubMedCrossRef
49.
Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Jackson HC, Huson L, Ward P, Oxford JS; Oseltamivir post exposure prophylaxis investigator group (2001) Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 285:748–754PubMedCrossRef
50.
Monto AS, Pichichero ME, Blanckenberg SJ, Ruuskanen O, Cooper C, Fleming DM, Kerr C (2002) Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 186:1582–1588PubMedCrossRef
51.
Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG (1999) Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1341:1336–1343CrossRef
52.
Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A (1999) Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 282:31–35PubMedCrossRef
53.
Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG (2001) Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 45:2723–2732PubMedCrossRef
54.
Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG (2001) The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 48:101–115CrossRef
55.
Govorkova EA, Fang HB, Tan M, Webster RG (2004) Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother 48:4855–4863PubMedCrossRef
56.
Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG (2007) Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 2007 Feb 12; (Epub ahead of print)
57.
Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, Chunsuthiwat S,Sawanpanyalert P, Kijphati R, Lochindarat S, Srisan P, Suwan P, Osotthanakorn Y, Anantasetagoon T, Kanjanawasri S, Tanupattarachai S, Weerakul J, Chaiwirattana R, Maneerattanaporn M, Poolsavathitikool R, Chokephaibulkit K, Apisarnthanarak A, Dowell SF (2005) Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis 11:201–209PubMed
58.
Ferraris O, Kessler N, Lina B (2005) Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res 68:43–48PubMedCrossRef
59.
Abed Y, Bourgault AM, Fenton RJ, Morley PJ, Gower D, Owens IJ, Tisdale M, Boivin G (2002) Characterization of 2 influenza A (H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. J Infect Dis 186:1074–1080PubMedCrossRef
60.
Abed Y, Baz M, Boivin G (2006) Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 11:971–976PubMed
61.
Ward P, Small I, Smith J, Suter P, Dutkowski R (2005) Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 55(Suppl 1):i5-i21PubMedCrossRef
62.
Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y (2004) Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759–765PubMedCrossRef
63.
Normile D, Enserink M (2007) Avian influenza. With change in the seasons, bird flu returns. Science 315:448PubMedCrossRef
64.
Oxford JS (2007) Antivirals for the treatment and prevention of epidemic and pandemic influenza. Influenza 1:27–34CrossRef
65.
Yen HL, Monto AS, Webster RG, Govorkova EA (2005) Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 192:665–672PubMedCrossRef
66.
Sidwell RW, Bailey KW, Bemis PA, Wong MH, Eisenberg EJ, Huffman JH (1999) Influence of treatment schedule and viral challenge dose on the in vivo influenza virus-inhibitory effects of the orally administered neuraminidase inhibitor GS 4104. Antivir Chem Chemother 10:187–193PubMed
67.
Massarella JW, He GZ, Dorr A, Nieforth K, Ward P, Brown A (2000) The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64–0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol 40:836–843PubMedCrossRef
68.
Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, Meijer A, van Steenbergen J, Fouchier R, Osterhaus A, Bosman A (2004) Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 363:587–593PubMedCrossRef
69.
Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG (1999) Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 43:1616–1620PubMed
70.
Ison MG, Gnann JW Jr, Nagy-Agren S, Treannor J, Paya C, Steigbigel R, Elliott M, Weiss HL, Hayden FG; NIAID Collaborative antiviral study group (2003) Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 8:183–190PubMed
71.
Cass LM, Efthymiopoulos C, Bye A (1999) Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 36(Suppl 1):1–11PubMedCrossRef
72.
Ilyushina NA, Bovin NV, Webster RG, Govorkova EA (2006) Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 70: 21–31CrossRef
73.
Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK (1972) Broad-spectrum antiviral activity of virazole: 1-β-d-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705–706PubMedCrossRef
74.
Khare GP, Sidwell RW, Witkowski JT, Simon LN, Robins RK (1973) Suppression by 1-β-d-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) of influenza virus-induced infections in mice. Antimicrob Agents Chemother 3:517–522PubMed
75.
Hong Z, Cameron CE (2002) Pleiotropic mechanisms of ribavirin antiviral activities. Prog Drug Res 59:41–69PubMed
76.
Gish RG (2006) Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 57:8–13PubMedCrossRef
77.
Stein DS, Creticos CM, Jackson GG, Bernstein JM, Hayden FG, Schiff GM, Bernstein DI (1987) Oral ribavirin treatment of influenza A and B. Antimicrob Agents Chemother 31:1285–1287PubMed
78.
Rodriguez WJ, Hall CB, Welliver R, Simoes EA, Ryan ME, Stutman H, Johnson G, Van Dyke R, Groothuis JR, Arrobio J (1994) Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J Pediatr 125:129–135PubMedCrossRef
79.
Hayden FG, Sable CA, Connor JD, Lane J (1996) Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection. Antivir Ther 1:51–56PubMed
80.
Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF (2005) In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res 68:10–17PubMedCrossRef
81.
Smee DF, Wandersee MK, Wong MH, Bailey KW, Sidwell RW (2004) Treatment of mannan-enhanced influenza B virus infections in mice with oseltamivir, ribavirin and viramidine. Antivir Chem Chemother 15:261–268PubMed
82.
Wu JZ, Walker H, Lau JY, Hong Z (2003) Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob Agents Chemother 47:426–431PubMedCrossRef
83.
Tran TH, Nguyen TL, Nguyen TD, Luong TS, Pham PM, Nguyen VC, Pham TS, Vo CD, Le TQ, Ngo TT, Dao BK, Le PP, Nguyen TT, Hoang TL, Cao VT, Le TG, Nguyen DT, Le HN, Nguyen KT, Le HS, Le VT, Christiane D, Tran TT, Menno de J, Schultsz C, Cheng P, Lim W, Horby P, Farrar J; World Health Organization international avian influenza investigative team (2004) Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 350:1179–1188PubMedCrossRef
84.
Oehling AG, Akdis CA, Schapowal A, Blaser K, Schmitz M, Simon HU (1997) Suppression of the immune system by oral glucocorticoid therapy in bronchial asthma. Allergy 52:144–154PubMedCrossRef
85.
86.
87.
Seo SH, Hoffmann E, Webster RG (2002) Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med 8:950–954PubMedCrossRef
88.
Seo SH, Hoffmann E, Webster RG (2004) The NS1 gene of H5N1 influenza viruses circumvents the host anti-viral cytokine responses. Virus Res 103:107–113PubMedCrossRef
89.
Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, Ng TK, Chan KH, Lai ST, Lim WL, Yuen KY, Guan Y (2004) Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363:617–619PubMedCrossRef
90.
Sauty A, Dziejman M, Taha RA, Iarossi AS, Neote K, Garcia-Zepeda EA, Hamid Q, Luster AD (1999) The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol 162:3549–3558PubMed
91.
Rainsford KD (2006) Influenza (“bird flu”), inflammation and anti-inflammatory/analgesic drugs. Inflammopharmacology 14:2–9PubMedCrossRef
92.
Huang RT, Dietsch E (1988) Anti-influenza viral activity of aspirin in cell culture. N Engl J Med 319:797PubMed
93.
Mazur I, Wurzer WJ, Ehrhardt C, Pleschka S, Puthavathana P, Silberzahn T, Wolff T, Planz O, Ludwig S (2007) Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-κB-inhibiting activity. Cell Microbiol (Epub ahead of print)
94.
D’Acquisto F, Ianaro A (2006) From willow bark to peptides: the ever widening spectrum of NF-κB inhibitors. Curr Opin Pharmacol 6:387–392PubMedCrossRef
95.
van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus AD, Kuiken T (2006) H5N1 virus attachment to lower respiratory tract. Science 312:399PubMedCrossRef
Metadata
Title
The threat of avian influenza A (H5N1). Part III: antiviral therapy
Authors
Jindrich Cinatl Jr
Martin Michaelis
Hans W. Doerr
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Medical Microbiology and Immunology / Issue 4/2007
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-007-0048-z

Other articles of this Issue 4/2007

Medical Microbiology and Immunology 4/2007 Go to the issue

Original Investigation

Pathogenesis of leptospirosis: interaction of Leptospira interrogans with in vitro cultured mammalian cells

Review

The threat of avian influenza A (H5N1). Part IV: development of vaccines

Review

The threat of avian influenza a (H5N1): part II: Clues to pathogenicity and pathology

Original Investigation

Immunogenicity and protective efficacy of the E. coli-expressed domain III of Japanese encephalitis virus envelope protein in mice

Rapid Communication

CCR5 and CCR3 expression on T CD3+ lymphocytes from HIV/Leishmania co-infected subjects

Original Investigation

Hepatitis B virus genotype E surface antigen detection with different immunoassays and diagnostic impact of mutations in the preS/S gene
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits